Project HOPE, Tuberculosis Control Programme for the Central Asia Region, Tashkent, Uzbekistan.
Int J Tuberc Lung Dis. 2009 Nov;13(11):1405-10.
Uzbekistan has had 100% DOTS coverage since 2005; however, the treatment success rate has remained at around 80% for the last 4 years. Surveys from the capital city of Tashkent and from western Uzbekistan have shown high levels of primary multidrug resistance.
To assess treatment regimens prescribed for new cases of tuberculosis (TB), including the prescription of additional non-TB drugs, and the cost implications for the patient.
We randomly sampled 30 clusters of seven new TB patients. Enrolled patients were interviewed and their medical records were reviewed.
In general, the treatment regimens prescribed were correct; doses were high rather than low. Second-line anti-tuberculosis drugs were rarely prescribed. In addition to anti-tuberculosis drugs, patients were prescribed on average seven to eight non-TB drugs. The rationale for prescribing the non-TB drugs was, however, questionable. Patients incurred substantial costs for these drugs, some of which were not without risk.
Prescriptions of anti-tuberculosis drugs for new TB patients are adequate; however, the practice of prescribing additional non-TB drugs needs to be reconsidered.
乌兹别克斯坦自 2005 年以来已实现了 100%直接督导下的短程化疗（DOTS）覆盖；然而，在过去的 4 年中，治疗成功率一直保持在 80%左右。来自塔什干首都和乌兹别克斯坦西部的调查显示，原发耐多药结核病的水平很高。
评估新结核病（TB）病例的治疗方案，包括额外的非结核病药物的处方，以及对患者的费用影响。
我们随机抽取了 30 个七个新结核病患者的群组。入组患者接受了访谈并审查了他们的病历。
一般来说，开出的治疗方案是正确的；剂量较高而不是较低。二线抗结核药物很少开。除抗结核药物外，患者平均还开了 7 到 8 种非结核病药物。开这些非结核病药物的理由值得商榷。患者为这些药物支付了大量费用，其中一些药物并非没有风险。
新结核病患者的抗结核药物处方是足够的；然而，需要重新考虑开具额外非结核病药物的做法。
